BioMedomics, Inc.
P.O. Box 14433,
27709
Durham, NC
6 Davis Drive, Research Triangle Park, 27709 Durham, NC
USA
6 Davis Drive, Research Triangle Park, 27709 Durham, NC
USA
This company is co-exhibitor of
Messe Düsseldorf North America
Location
Hall map
Fairground map
Our range of products
Product categories
- 03 Diagnostic Tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.02 Diagnostic rapid tests
Diagnostic rapid tests
Our products
Product category: Diagnostic rapid tests
Sickle SCAN®
Detects sickle cell disease and trait in 5 minutes
Sickle SCAN is a rapid, qualitative POC test for Sickle Cell Disease developed by BioMedomics. Currently SCD can only be accurately tested using complex and expensive central laboratory equipment, which limits SCD screening programs in developing countries that lack the necessary infrastructure. As a result, these areas suffer 50%-90% mortality rates for newborns with Sickle Cell Disease despite the availability of inexpensive lifesaving treatments. There is an acute medical need for a simple, inexpensive SCD test for the 36 million annual births in these at risk areas.
Sickle SCAN's multiplexed, qualitative, point-of-care immunoassay consists of three indicators which detect the presence of hmoglobins A, S, and C. This allows the user to rapidly distinguish between normal, carrier, and sickle cell blood samples. The test can be completed in under five minutes, and uses a small amount of whole blood from fingerstick, heelstick, or venipuncture. Compared to traditional central lab testing, Sickle SCAN eliminates the need to transport blood samples, streamlines clinical workflow, and does not require expensive equipment, sensitive agents, or specialized training.
Sickle SCAN is ideal for newborn screening, premarital/preconception genetic counseling, blood donor screening, and general population screening.
Sickle SCAN is a rapid, qualitative POC test for Sickle Cell Disease developed by BioMedomics. Currently SCD can only be accurately tested using complex and expensive central laboratory equipment, which limits SCD screening programs in developing countries that lack the necessary infrastructure. As a result, these areas suffer 50%-90% mortality rates for newborns with Sickle Cell Disease despite the availability of inexpensive lifesaving treatments. There is an acute medical need for a simple, inexpensive SCD test for the 36 million annual births in these at risk areas.
Sickle SCAN's multiplexed, qualitative, point-of-care immunoassay consists of three indicators which detect the presence of hmoglobins A, S, and C. This allows the user to rapidly distinguish between normal, carrier, and sickle cell blood samples. The test can be completed in under five minutes, and uses a small amount of whole blood from fingerstick, heelstick, or venipuncture. Compared to traditional central lab testing, Sickle SCAN eliminates the need to transport blood samples, streamlines clinical workflow, and does not require expensive equipment, sensitive agents, or specialized training.
Sickle SCAN is ideal for newborn screening, premarital/preconception genetic counseling, blood donor screening, and general population screening.
About us
Company details
BioMedomics creates lifesaving clinical diagnostics technologies by delivering accurate, quick, simple and affordable solutions for use anywhere, anytime. We are committed to developing and marketing products that provide immediate answers wherever you are, deliver point-of-care results equivalent to large laboratories, and use cutting edge technology to achieve reliable results.